One recent QSP model explored the current assumptions underlying the therapeutic mechanism of interleukin-1β (IL-1β) blockade in type-2 diabetes mellitus (T2DM) [65] [BioModels: MODEL1604 270002]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.